


## LISTING OF CLAIMS


Please amend the claims as follows:

1. (Previously amended) A pharmaceutically acceptable salt of formula (I)



its stereoisomers, wherein  $R^1$  represents ethyl; M represents phenyl glycinol, methyl benzylamine, dicyclohexylamine, tris (hydroxymethyl)amino methane, N-octyl glucamine, N-methyl glucamine, amino guanidine hydrogen carbonate, metformin, imidazole, methyl benzylamine, S-(+)-phenylglycinol, aminoguanidine, tromethamine, *t*-butylamine, tris (hydroxymethyl) amino methane; p is an integer ranging from 1 to 2;


A represents a cyclic structure given below:




wherein  $R^2$  represents methyl;  $R^3$  represents ethyl, propyl;  $R^4$  represents methyl, ethyl, azido, morpholinyl, piperidinyl.

2. (Canceled)


3. (Withdrawn) A process for the preparation of a pharmaceutically acceptable salt of the formula (I) or its stereoisomers



which comprises: reacting a compound of the formula (III)



wherein  $\text{R}^1$  represents hydrogen, alkyl or aryl group; A represents a cyclic structure given below:



where  $\text{R}^2$  and  $\text{R}^3$  are the same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, alkyl, or alkoxy group;  $\text{R}^4$  represents hydrogen, halogen, hydroxy, nitro, cyano, azido, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, aryl, heterocyclyl, heteroaryl, amino, monoalkylamino, dialkylamino or alkoxyalkyl group, with a stoichiometric amount of a base in the presence of a solvent.

4. (Withdrawn) The process as claimed in claim 3, wherein the base used is selected from sodium hydroxide, sodium methoxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, magnesium hydroxide, glucamine, N-methylglucamine, N-octylglucamine, dicyclohexylamine, t-butylamine, methyl benzylamine, tris(hydroxymethyl)aminomethane, phenyl glycinol, lysine, arginine, metformin,

aminoguanidine, aminoguanidine hydrogen carbonate, imidazole, piperazine, dimethyl piperazine, pyrrolidine, benzylamine, phenyl glycine methyl ester, phenylalanine benzyl ester or morpholine.

5. (Withdrawn) The process as claimed in claim 3, wherein the reaction is effected in the presence of solvent selected from alcohols, ketones, ethers, DMF, DMSO, xylene, toluene, ethyl acetate or a mixture thereof.

6. (Withdrawn) The process as claimed in claim 4, wherein the reaction is effected in the presence of solvent selected from alcohols, ketones, ethers, DMF, DMSO, xylene, toluene, ethyl acetate or a mixture thereof.

7. (Withdrawn) The process as claimed in claim 3, wherein the reaction is carried out at a temperature in the range of  $-10^{\circ}\text{C}$ . to the boiling point of the solvent employed for a period in the range of 10 minutes to 30 hours.

8. (Withdrawn) The process as claimed in claim 4, wherein the reaction is carried out at a temperature in the range of  $-10^{\circ}\text{C}$ . to the boiling point of the solvent employed for a period in the range of 10 minutes to 30 hours.

9. (Withdrawn) The process as claimed in claim 5, wherein the reaction is carried out at a temperature in the range of  $-10^{\circ}\text{C}$ . to the boiling point of the solvent employed for a period in the range of 10 minutes to 30 hours.

10 (Withdrawn) The process as claimed in claim 6, wherein the reaction is carried out at a temperature in the range of  $-10^{\circ}\text{C}$ . to the boiling point of the solvent employed for a period in the range of 10 minutes to 30 hours.

11- 12. (Canceled)

13. (Previously amended) A pharmaceutical composition which comprises a compound as claimed in claim 1 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

14. (Previously amended) A pharmaceutical composition which comprises a compound as defined in claim 1, and an HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, cholestipol, probucol or a mixture thereof and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

15.-16. (Canceled)

17. (Original) A pharmaceutical composition as claimed in claim 13, in the form of a tablet, capsule, powder, syrup, solution or suspension.

18. (Original) A pharmaceutical composition as claimed in claim 14, in the form of a tablet, capsule, powder, syrup, solution or suspension.

19.-63. (Canceled)

64. (Withdrawn) The process as claimed in claim 5, wherein the alcohol is selected from a group consisting of ethanol, methanol, isopropanol and butanol; ketone is selected from a group consisting of acetone, diethyl ketone, and methyl ethyl ketone; and ether is selected from a group consisting of diethyl ether, ether, tetrahydrofuran, dioxane, and dibutyl ether.

65. (Withdrawn) The process as claimed in claim 6 wherein the alcohol is selected from a group consisting of ethanol, methanol, isopropanol and butanol; ketone is selected from a group consisting of acetone, diethyl ketone, and methyl ethyl ketone; and ether is selected from a group consisting of diethyl ether, ether, tetrahydrofuran, dioxane, and dibutyl ether.

66. (Previously presented) The pharmaceutically acceptable salt according to claim 1, which is selected from:

- (±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
phenyl]-2-ethoxypropanoic acid phenyl glycinol salt;  
(+) 3- [4- [2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
phenyl]-2-ethoxypropanoic acid phenyl glycinol salt;  
(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]

phenyl]-2-ethoxypropanoic acid phenyl glycinol salt;  
 (±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid methyl benzylamine salt;  
 (+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid methyl benzylamine salt;  
 (-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid methyl benzylamine salt;  
 (±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid dicyclohexylamine salt;  
 (+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid dicyclohexylamine salt;  
 (-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid dicyclohexylamine salt;  
 (±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid tris (hydroxymethyl)amino methane salt  
 (+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid tris (hydroxymethyl)amino methane salt;  
 (-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid tris (hydroxymethyl)amino methane salt;  
 (±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid N-octyl glucamine salt;  
 (+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid N-octyl glucamine salt;  
 (-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid N-octyl glucamine salt;  
 (±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid N-methyl glucamine salt;  
 (+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid N-methyl glucamine salt;  
 (-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]  
 phenyl]-2-ethoxypropanoic acid N-methyl glucamine salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid amino guanidine hydrogen carbonate salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid amino guanidine hydrogen carbonate salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid amino guanidine hydrogen carbonate salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid lithium salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid lithium salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid lithium salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid metformin salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid metformin salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid metformin salt;

(±) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid imidazole salt;

(+) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid imidazole salt;

(-) 3-[4-[2-(2-Ethyl-4-oxo-3,4-dihydroquinazolin-3-yl)ethoxy]phenyl]-2-ethoxypropanoic acid imidazole salt.

67. (Currently amended) The pharmaceutically acceptable salt according to claim 1, which is selected from:

(±)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl benzylamine salt;

(+)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo

[4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl benzyl-amine salt;

(-)-3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl benzyl-amine salt;

(±)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenyl-glycinol salt;

(+)-3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenyl-glycinol salt;

(-)-3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenyl-glycinol salt;

(±)3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(+)-3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine

salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexylamine salt;

(+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexylamine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexylamine salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octylglucamine salt;

(+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octylglucamine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octylglucamine salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methylglucamine salt;

(+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methylglucamine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methylglucamine salt;

(±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;

(+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo



[4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;  
 (-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo  
 [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;  
 (±) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo  
 [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tbutylamine salt;  
 (+) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo  
 [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tbutylamine salt;  
 (-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo  
 [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tbutylamine salt;  
 (±)-3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo  
 [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid aminoguanidine  
 hydrogen carbonate salt;  
 (+)-3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo  
 [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid aminoguanidine  
 hydrogen carbonate salt;  
 (-)-3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo  
 [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid aminoguanidine  
 hydrogen carbonate salt.

68. (Previously presented) The pharmaceutically acceptable salt according to claim 1,  
 which is selected from:

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo  
 [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl  
 benzylamine salt;  
 (+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo  
 [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl  
 benzylamine salt;  
 (-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo  
 [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid methyl  
 benzylamine salt;  
 (±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo

[4,3-d]pyridin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenylglycinol salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenylglycinol salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid S-(+)-phenylglycinol salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid amino-guanidine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tromethamine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexylamine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexyl-

amine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1 H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid dicyclohexyl-amine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro- 1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octyl-glucamine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro- 1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octyl-glucamine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-octyl-glucamine salt;

(±) 3- [4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro- 1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methyl-glucamine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methyl-glucamine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid N-methyl-glucamine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro- 1 H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3 -propyl-6,7-dihydro- 1 H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid metformin salt;

(±) 3- [4-[2-(1,5-Dimethyl-7-oxo-3 -propyl-6,7-dihydro- 1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxyprop<sup>i</sup>o<sup>nic</sup> acid tbutylamine salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1 H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tbutylamine salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1 H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid tbutylamine salt;

(±) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid aminoguanidine hydrogen carbonate salt;

(+) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxy propionic acid aminoguanidine hydrogen carbonate salt;

(-) 3-[4-[2-(1,5-Dimethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid aminoguanidine hydrogen carbonate salt;

69. (Currently amended) The pharmaceutically acceptable salt according to claim 1, which is selected from:

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid phenyl glycinol salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid phenyl glycinol salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid phenyl glycinol salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid methyl benzylamine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid methyl benzylamine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid methyl benzylamine salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-

yl] ethoxy]phenyl]propanoic acid t-butylamine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid t-butylamine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid t-butylamine salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-methyl glucamine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-methyl glucamine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-methyl glucamine salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-octyl glucamine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-octyl glucamine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid N-octyl glucamine salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid tris (hydroxymethyl) amino methane salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid tris (hydroxymethyl) amino methane salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid tris (hydroxymethyl) amino methane salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid lithium salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid lithium salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid lithium salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid metformin salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid metformin salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid metformin salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid dicyclohexylamine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid dicyclohexylamine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid dicyclohexylamine salt;

(±) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid aminoguanidine salt;

(+) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid aminoguanidine salt;

(-) 2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid aminoguanidine salt;

70. (New) The pharmaceutically acceptable salt according to claim 1, which is selected from:

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid magnesium salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid potassium salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid calcium salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid lithium salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid lithium salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid sodium salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid arginine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid R-(+)methyl benzylamine salt;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid;

(-) 3-[4-[2-(1-Methyl-5-ethyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo [4,3-d]pyrimidin-6-yl)ethoxy]phenyl]-2-ethoxypropionic acid lysine salt.

71. (New) A pharmaceutical composition which comprises a compound as claimed in claim 66 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

72. (New) A pharmaceutical composition which comprises a compound as defined in claim 66, and an HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, cholestipol, probucol or a mixture thereof and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

73. (New) A pharmaceutical composition as claimed in claim 71, in the form of a tablet, capsule, powder, syrup, solution or suspension.

74. (New) A pharmaceutical composition as claimed in claim 72, in the form of a tablet, capsule, powder, syrup, solution or suspension.

75. (New) A pharmaceutical composition which comprises a compound as claimed in claim 67 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

76. (New) A pharmaceutical composition which comprises a compound as defined in claim 67, and an HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, cholestipol, probucol or a mixture thereof and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

77. (New) A pharmaceutical composition as claimed in claim 75, in the form of a tablet, capsule, powder, syrup, solution or suspension.

78. (New) A pharmaceutical composition as claimed in claim 76, in the form of a tablet, capsule, powder, syrup, solution or suspension.

79. (New) A pharmaceutical composition which comprises a compound as claimed in claim 68 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

80. (New) A pharmaceutical composition which comprises a compound as defined in claim 68, and an HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, cholestipol, probucol or a mixture thereof and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

81. (New) A pharmaceutical composition as claimed in claim 79, in the form of a tablet, capsule, powder, syrup, solution or suspension.

82. (New) A pharmaceutical composition as claimed in claim 80, in the form of a tablet, capsule, powder, syrup, solution or suspension.

83. (New) A pharmaceutical composition which comprises a compound as claimed in claim 69 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

84. (New) A pharmaceutical composition which comprises a compound as defined in claim 69, and an HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, cholestipol, probucol or a mixture thereof and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

85. (New) A pharmaceutical composition as claimed in claim 83, in the form of a tablet, capsule, powder, syrup, solution or suspension.

86. (New) A pharmaceutical composition as claimed in claim 84, in the form of a tablet, capsule, powder, syrup, solution or suspension.



87. (New) A pharmaceutical composition which comprises a compound as claimed in claim 70 and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

88. (New) A pharmaceutical composition which comprises a compound as defined in claim 70, and an HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, cholestipol, probucol or a mixture thereof and a pharmaceutically acceptable carrier, diluent, excipient or solvate.

89. (New) A pharmaceutical composition as claimed in claim 87, in the form of a tablet, capsule, powder, syrup, solution or suspension.

90. (New) A pharmaceutical composition as claimed in claim 88, in the form of a tablet, capsule, powder, syrup, solution or suspension.

91. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a compound as defined in claim 1 to a patient in need thereof.

92. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a compound as defined in claim 66 to a patient in need thereof.

93. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a compound as defined in claim 67 to a patient in need thereof.

94. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a compound as defined in claim 68 to a patient in need thereof.

95. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a compound as defined in claim 69 to a patient in need thereof.

96. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a compound as defined in claim 70 to a patient in need thereof.

97. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 13 to a patient in need thereof.

98. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 14 to a patient in need thereof.

99. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 71 to a patient in need thereof.

100. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 72 to a patient in need thereof.

101. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 75 to a patient in need thereof.

102. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 76 to a patient in need thereof.

103. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 79 to a patient in need thereof.

104. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 80 to a patient in need thereof.

105. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 83 to a patient in need thereof.

106. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 84 to a patient in need thereof.

107. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 87 to a patient in need thereof.

108. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering a pharmaceutical composition as defined in claim 88 to a patient in need thereof.

109. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a compound of formula (I) as defined in claim 1 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

110. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a compound of as claimed in claim 66 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

111. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a compound of as claimed in claim 67 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

112. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a compound of as claimed in claim 68 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

113. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a compound of as claimed in claim 69 in combination/concomittant with a

HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

114. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a compound of as claimed in claim 70 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

115. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 13 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

116. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 71 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

117. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 75 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

118. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 79 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

119. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 83 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.

120. (New) A method of treating hyperlipidemia, hypercholesteremia, hyperglycemia, insulin resistance, psoriasis, obesity, leptin resistance and type II diabetes comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 87 in combination/concomittant with a HMG CoA reductase inhibitor, fibrate, nicotinic acid, cholestyramine, colestipol or probucol or a mixture thereof within such a period so as to act synergistically.